Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
featured
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

aplastic anemia
myelodysplastic syndromes
myelodysplastic syndrome (mds)
anemia studies
anemia
  • 61 views
  • 22 Dec, 2020
  • 1 location
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

patients is still poor with median survival of less than 20 months. Everolimus is an mammilian target of rapamycin (mTOR) inhibitor that has been demonstrated to be active in patients with well and

serum bilirubin
neutrophil count
etoposide
renal function
ki-67
  • 0 views
  • 23 Jan, 2021
  • 5 locations
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

missing self on their graft responsible for a NK-mediated rejection will be established prospectively. An mTOR inhibitor will be introduced in these patients for 6 months in association with a calcineurin

  • 0 views
  • 03 May, 2021
  • 1 location
Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

associated with these drugs. The aim of our study is to evaluate the effect of the mTor inhibitor everolimus on the prevention of severe BKV infection (BKV nephropathy or loss of the allograft) after kidney

  • 18 views
  • 23 Jan, 2021
  • 11 locations
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

cycle regulation. We propose to evaluate pharmacodynamic assessments of the mTOR inhibitor RAD001 in intermediate and high risk prostate cancer patients in the neoadjuvant setting. Patients

adenocarcinoma of prostate
tumor progression
PTEN
castration-resistant prostate cancer
adenocarcinoma
  • 3 views
  • 07 Nov, 2020
  • 1 location
Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

blood test
reticulocyte count
cyclosporine
neutrophil count
white blood cells
  • 7 views
  • 02 Apr, 2021
  • 1 location
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation

The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day delay of cyclosporine in combination with MMF.

everolimus
liver transplant
cyclosporine
immunosuppression
  • 12 views
  • 08 Nov, 2020
  • 1 location
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

hematopoietic growth factors
absolute neutrophil count
nervous
selumetinib sulfate
antibody therapy
  • 990 views
  • 28 Jul, 2021
  • 114 locations
ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension

animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

left ventricular end-diastolic pressure
pulmonary arterial hypertension
congenital heart defects
pulmonary function test
primary pulmonary hypertension
  • 0 views
  • 27 Feb, 2021
  • 6 locations
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.

absolute neutrophil count
cancer
platelet count
weakness
ejection fraction
  • 37 views
  • 25 Jan, 2021
  • 4 locations